Can your genes make you more prone to pneumococcal disease?

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 9, 2010, Pages 967-972

  Chapman, Stephen J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

mannose binding lectin; nuclear factor B; polymorphism; PTPN22; Streptococcus pneumoniae; Toll like receptors

Indexed keywords

I KAPPA B; I KAPPA B KINASE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MANNOSE BINDING LECTIN; MYELOID DIFFERENTIATION FACTOR 88; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TOLL LIKE RECEPTOR;

AGE; AUTOIMMUNITY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CIGARETTE SMOKING; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; EDITORIAL; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALNUTRITION; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; RISK FACTOR; SEROTYPE; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MANNOSE-BINDING LECTIN; NF-KAPPA B; PNEUMONIA, PNEUMOCOCCAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE; TOLL-LIKE RECEPTORS;

EID: 77956476845     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.84     Document Type: Editorial

References (83)

1. World Health Organization. Pneumococcal vaccines. Wkly Epidemiol. Rec. 14, 110-119 (2003).
2. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56(Suppl. IV), iv1-iv64 (2001).
3. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4, 144-154 (2004). (Pubitemid 38293138)
4. Musher DM. Streptococcus pneumoniae. In: Principles and Practice of Infectious Disease. Mandell GL, Bennett JE, Dolin R (Eds.). Churchill Livingstone, PA, USA, 2392-2411 (2004).
5. Talbot TR, Hartert TV, Mitchel E et al Asthma as a risk factor for invasive pneumococcal disease. N. Engl. J. Med. 352, 2082-2090 (2005).
6. Parsons HK, Dockrell DH. The burden of invasive pneumococcal disease and the potential for reduction by immunisation. Int. J. Antimicrob. Agents 19, 85-93 (2002).
7. Grant CC, Harnden AR, Jewell G, Knox K, Peto TE, Crook DW. Invasive pneumococcal disease in Oxford, 1985-2001: a retrospective case series. Arch. Dis. Child. 88, 712-714 (2003).
8. Cooke GC, Hill AVS. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2, 967-977 (2001).
9. Weatherall DJ, Clegg JB. Genetic variability in response to infection: malaria and after. Genes Immun. 3, 331-337 (2002).
10. Sorensen TIA, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental infuences on premature death in adult adoptees. N. Engl. J. Med. 318, 727-732 (1988).
11. Gingles NA, Alexander JE, Kadioglu A et al. Role of genetic resistance in invasive pneumococcal infection: identifcation and study of susceptibility and resistance in inbred mouse strains. Infect. Immun. 69(1), 426-434 (2001).
12. Kerr AR, Irvine JJ, Search JJ et al. Role of infammatory mediators in resistance and susceptibility to pneumococcal infection. Infect. Immun. 70(3), 1547-1557 (2002).
13. Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and metaanalysis. Lancet Infect. Dis. 9(1), 31-44 (2009).
14. Picard C, Puel A, Bustamante J, Ku C-L, Casanova J-L. Primary immunodefciencies associated with pneumococcal disease. Curr. Opin. Allergy Clin. Immunol. 3, 451-459 (2003).
15. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
16. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
17. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163(1), 1-5 (1999).
18. Schroder NW, Morath S, Alexander C et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278, 15587-15594 (2003).
19. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus infuenzae, and Neisseria meningitides activate the infammatory response through Toll-like receptors 2, 4, and 9 in species-specifc patterns. J. Leukocyte Biol. 80, 1-11 (2006).
20. Letiembre M, Echchannaoui H, Bachmann P et al. Toll-like receptor 2 defciency delays pneumococcal phagocytosis and impairs oxidative killing by granulocytes. Infect. Immun. 73, 8397-8401 (2005).
21. Malley R, Henneke P, Morse SC et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl Acad. Sci. USA 100(4), 1966-1971 (2003).
22. Spellerberg B, Rosenow C, Sha W, Tuomanen EI. Pneumococcal cell wall activates NF-KB in human monocytes: aspects distinct from endotoxin. Microb. Pathog 20, 309-317 (1996).
23. Schmeck B, Zahlten J, Moog K et al Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleuin-8 promoter. J. Biol. Chem. 279(51), 53241-53247 (2004).
24. Amory-Rivier CF, Mohler J, Bedos JP et al Nuclear factor-KB activation in mouse lung lavage cells in response to Streptococcus pneumoniae pulmonary infection. Crit. Care Med. 28(9), 3249-3256 (2000).
25. Jones MR, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Lung NF-KB activation and neutrophils recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J. Immunol. 175, 7530-7535 (2005).
26. Quinton LJ, Jones MR, Simms BT et al Functions and regulation of NF-KB RelA during pneumococcal pneumonia. J. Immunol. 178, 1896-1903 (2007).
27. Von Bernuth H, Picard C, Jin Z et al. Pyogenic bacterial infections in humans with MyD88 defciency. Science 321(5889), 691-696 (2008).
28. Zonana J, Elder ME, Schneider LC et al. A novel X-linked disorder of immune defciency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-y (NEMO). Am. J. Hum. Genet. 67, 1555-1562 (2000).
29. Mansour S, Woffendin H, Mitton S et al Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection. Am. J. Med. Genet. 99, 172-177 (2001).
30. Doffnger R, Smahi A, Bessia C et al X-linked anhidrotic ectodermal dysplasia with immunodefciency is caused by impaired NF-KB signaling. Nat. Genet. 27, 277-285 (2001).
31. Picard C, Puel A, Bonnet M et al. Pyogenic bacterial infections in humans with IRAK-4 defciency. Science 299, 2076-2079 (2003).
32. Courtois G, Smahi A, Reichenbach J et al A hypermorphic IKBa mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodefciency. J. Clin. Invest. 112, 1108-1115 (2003).
33. Janssen R, van Wengen A, Hoeve MA et al The same IkBa mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 200, 559-568 (2004).
34. Puel A, Picard C, Ku CL, Smahi A, Casanova JL. Inherited disorders of NF-kB-mediated immunity in man. Curr. Opin. Immunol. 16, 34-41 (2004).
35. Medvedev AE, Lentschat A, Kuhns DB et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521-531 (2003).
36. Chapman SJ, Khor CC, Vannberg FO et al. IkB genetic polymorphisms and invasive pneumococcal disease. Am. J. Respir. Crit. Care Med. 176, 181-187 (2007).
37. Chapman SJ, Khor CC, Vannberg FO et al. NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations. Genes Immun. 11(4), 319-325 (2010).
38. Abraham E. Alterations in cell signaling in sepsis. Clin. Infect. Dis. 41, S459-S464 (2005).
39. Koedel U, Bayerlein I, Paul R, Sporer B, Pfster HW. Pharmacological interference with NF-kB activation attenuates central nervous system complications in experimental pneumococcal meningitis. J. Infect. Dis. 182, 1437-1445 (2000).
40. Tak PP, Firestein GS. NF-kB: a key role in infammatory diseases. J. Clin. Invest. 107(1), 7-11 (2001).
41. Karin M, Yamamoto Y, Wang QM. The IKK NF-kB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17-26 (2003).
42. Yamamoto M, Sato S, Hemmi H et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420, 324-329 (2002).
43. Khor CC, Chapman SJ, Vannberg FO et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat. Genet. 39(4), 523-528 (2007).
44. Ferwerda B, Alonso S, Banahan K et al Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc. Natl Acad. Sci. USA 106(25), 10272-10277 (2009).
45. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 415, 673-679 (2002).
46. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 365(9453), 63-78 (2005).
47. Cundell DR, Gerard NP, GerardC, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377, 435-438 (1995).
48. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 37, 1496-1505 (2003).
49. Mullighan CG, Heatley S, Doherty K et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 99, 3524-3529 (2002).
50. Kilpatrick DC. Mannan-binding lectin: clinical signifcance and applications. Biochim. Biophys. Acta 1572, 401-413 (2002).
51. Summerfeld JA, Sumiya M, Levin M et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. Br. Med. J. 314, 1229-1232 (1997).
52. Roy S, Knox K, Segal S et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 359, 1569-1573 (2002).
53. Kronborg G, Garred P. Mannose-binding lectin genotype as a risk factor for invasive pneumococcal infection. Lancet 360, 1176 (2002).
54. Hibberd ML, Sumiya M, Summerfeld JA et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 353, 1049-1053 (1999).
55. Koch A, Melbye M, Sorensen P et al. Acute respiratory tract infections and mannose-binding lectin insuffciency during early childhood. JAMA 285, 1316-1321 (2001).
56. Garred P, Strom JJ, Quist L et al. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic infammatory response syndrome. J. Infect. Dis. 188, 1394-1403 (2003).
57. Peterslund NA, Koch C, Jensenius JC et al. Association between defciency of mannose-binding lectin and severe infections after chemotherapy. Lancet 358, 636-638 (2001).
58. Neth O, Hann I, Turner MW et al. Defciency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358, 614-618 (2001).
59. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J. Allergy Clin. Immunol. 122(2), 368-374 (2008).
60. Endeman H, Herpers BL, de Jong BA et al. Mannose-binding lectin genotypes in susceptibility to community acquired pneumonia. Chest 134(6), 1135-1140 (2008).
61. Rantala A, Lajunen T, Juvonen R et al. Mannose-binding lectin concentrations, MBL2 polymorphisms, and susceptibility to respiratory tract infections in young men. J. Infect. Dis. 198(8), 1247-1253 (2008).
62. Eisen DP, Dean MM, Boermeester MA et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin. Infect. Dis. 47(4), 510-516 (2008).
63. Stengaard-Pedersen K, Thiel S, Gadjeva M et al. Inherited defciency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 349, 554-560 (2003). (Pubitemid 36951367)
64. Bottini N, Musumeci L, Alonso A et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337-338 (2004).
65. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: setting thresholds for autoimmunity. Sem. Immunol. 18, 214-223 (2006).
66. Begovich AB, Carlton VE, Honigberg LA et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330-337 (2004).
67. Kyogoku C, Langefeld CD, Ortmann WA et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75, 504-507 (2004).
68. Carlton VEH, Hu X, Chokkalingam AP et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 7 7, 567-581 (2005).
69. Smyth D, Cooper JD, Collins JE et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53, 3020-3023 (2004).
70. Velaga MR, Wilson V, Jennings CE et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J. Clin. End. Met. 89, 5862-5865 (2004).
71. Canton I, Akhtar S, Gavalas NG et al. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun. 6, 584-587 (2005).
72. Michou L, Lasbleiz S, Rat AC et al. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc. Natl Acad. Sci. USA 104, 1649-1654 (2007).
73. Siminovitch KA. PTPN22 and autoimmune disease. Nat. Genet. 36, 1248-1249 (2004).
74. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
75. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Sem. Immunol. 18, 207-213 (2006).
76. Gregersen PK. Gaining insight into PTPN22 and autoimmunity. Nat. Genet. 37, 1300-1302 (2005).
77. Vang T, Congia M, Macis MD et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317-1319 (2005).
78. Arechiga AF, Habib T, He Y et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J. Immunol. 182(6), 3343-3347 (2009).
79. Chapman SJ, Khor CC, Vannberg FO et al. PTPN22 and invasive bacterial disease. Nat. Genet. 38(5), 499-500 (2006).
80. Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat. Rev. Genet. 11(1), 17-30 (2010).
81. McCarthy MI, Abecasis GR, Cardon LR et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008).
82. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet. 40(6), 695-701 (2008).
83. Casanova JL, Abel L. Primary immunodefciencies: a feld in its infancy. Science 317(5838), 617-619 (2007).